FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer

2017 ◽  
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

2021 ◽  
Vol 22 (8) ◽  
pp. 1139-1150
Author(s):  
Rosie Bradley ◽  
Jeremy Braybrooke ◽  
Richard Gray ◽  
Robert Hills ◽  
Zulian Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Randomised Trials ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?

2020 ◽  
Vol 20 (6) ◽  
pp. 503-510
Author(s):  
Haiping Lin ◽  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Qinghua Wang ◽  
Wanfen Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

2019 ◽  
Vol 12 (4) ◽  
pp. 312-314 ◽  
Author(s):  
Christoph Suppan ◽  
Marija Balic
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Early Stage ◽  
Postoperative Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Adjuvant Breast Cancer ◽  
American Society ◽  
Positive Breast Cancer

Summary Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.

Sign in / Sign up

Export Citation Format

Share Document